Chronic Myeloid Leukemia Treatment

CME

Chronic Myeloid Leukemia: Optimizing Use of TKIs to Individualize Treatment Across the Disease Spectrum

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 15, 2024

Expiration: February 14, 2025

Fadi Haddad
Fadi Haddad, MD

Activity

Progress
1 2
Course Completed

References

  1. Kennedy JA, Hobbs G. Tyrosine kinase inhibitors in the treatment of chronic-phase CML: Strategies for frontline decision-making. Curr Hematol Malig Rep. 2018;13:202-211.
  2. Senapati J, Sasaki K, Issa GC, et al. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023;13:58.
  3. Imatinib [prescribing information]. East Hanover, NJ: Novartis; 2022.
  4. Bosutinib [prescribing information]. New York, NY: Pfizer; 2023.
  5. Dasatinib [prescribing information]. Princeton, NJ: Bristol Myers Squibb; 2023.
  6. Nilotinib [prescribing information]. East Hanover, NJ: Novartis; 2024.
  7. Ponatinib [prescribing information]. Cambridge, MA: Takeda; 2024.
  8. Asciminib [prescribing information]. East Hanover, NJ: Novartis; 2021.
  9. Ford M, Mauro M, Aftandilian C, et al. Management of chronic myeloid leukemia in children and young adults. Curr Hematol Malig Rep. 2022;17:121-126.
  10. Gener-Ricos G, Haddad FG, Sasaki K, et al. Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results. Clin Lymphoma Myeloma Leuk. 2023;23:742-748.
  11. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28:424-430.
  12. Kim DW. Recent advances in the path toward the cure for chronic myeloid leukemia. Korean J Hematol. 2011;46:169-174.
  13. Branford S, Fernandes A, Shahrin N, et al. Beyond BCR::ABL1–The role of genomic analyses in the management of CML. J Natl Compr Canc Netw. 2024;22.
  14. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917-927.
  15. Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440-453.
  16. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333-2340.
  17. Brummendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36:1825-1833.
  18. Hochhaus A, Wang J, Kim DW, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;[Epub ahead of print].
  19. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic myeloid leukemia. v.2.2024. nccn.org. Accessed August 6, 2024.
  20. Haddad FG, Sasaki K, Issa GC, et al. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022;97:856-864.
  21. Shanmuganathan N, Hughes TP. Molecular monitoring in CML: How deep? How often? How should it influence therapy? Hematology Am Soc Hematol Educ Program. 2018;2018:168-176.
  22. Cross NC, Hochhaus A, Muller MC. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol. 2015;94 Suppl 2:S219-225.
  23. Kantarjian HM, Jabbour EJ, Lipton JH, Castagnetti F, Brummendorf TH. A review of the therapeutic role of bosutinib in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2024;24:285-297.
  24. Chen H, Wen Y, Zeng Y, et al. Patient versus physician perspective in the management of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Oncol Ther. 2024;12:131-145.
  25. Haddad FG, Kantarjian H. Navigating the management of chronic phase CML in the era of generic BCR::ABL1 tyrosine kinase inhibitors. J Natl Compr Canc Netw. 2024;22.
  26. Russo D, Malagola M, Polverelli N, Farina M, Re F, Bernardi S. Twenty years of evolution of CML therapy: How the treatment goal is moving from disease to patient. Ther Adv Hematol. 2023;[Epub ahead of print];14:20406207231216077.
  27. Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375-e383.
  28. Malagola M, Iurlo A, Bucelli C, et al. The Italian multicentric randomized OPTkIMA trial on fixed vs progressive intermittent TKI therapy in CML elderly patients: 3-years of molecular response and quality of life monitoring after completing the treatment plan. Clin Lymphoma Myeloma Leuk. 2024;24:323-331.
  29. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112:837-845.
  30. Oriana C, Martin H, Toby P, et al. Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. Value Health. 2013;16:1081-1090.
  31. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758-3765.
  32. Cortes JE, Sasaki K, Kim DW, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024;38:1522-1533.
  33. Jabbour E, Kantarjian H, Ghanem H, et al. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013;13:302-306.
  34. Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41-iv51.
  35. Hughes TP, Leber B, Cervantes F, et al. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017;31:2529-2531.
  36. Hughes TP, Saglio G, Geissle J, et al. Asciminib (ASC) add-on to imatinib (IMA) demonstrates sustained high rates of ongoing therapy and deep molecular responses (DMRs) with prolonged follow-up in the ASC4MORE study. Presented at: 63rd Annual Meeting of the American Society of Hematology; December 9-12, 2023. Abstract 866.
  37. Shah NP, Cortes JE, Schiffer CA, et al. Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. J Clin Oncol. 2010;28:15s.
  38. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317-2324.
  39. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141-1145.
  40. Gambacorti-Passerini C, Brummendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014;89:732-742.
  41. Cortes JE, Jiang Q, Wang J, et al. Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN. Haematologica. 2024;[Epub ahead of print].
  42. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393-404.
  43. Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042-2050.
  44. Cortes J, Deininger M, Lomaia E, et al. Long-term results from the OPTIC trial: A dose-optimization study of 3 starting doses of ponatinib. Blood. 2023;142(suppl 1):3164-3166.
  45. Apperley J, Deininger M, Arthur C, et al. Outcomes with ponatinib in patients with chronic-phase chronic myeloid leukemia and the T315I mutation: 4-year results from the OPTIC trial. Presented at: 29th annual European Hematology Association Congress; June 13-16, 2024. Abstract S173.
  46. Andorsky D, Kota V, Sweet K. Exploring treatment decision-making in chronic myeloid leukemia in chronic phase. Front Oncol. 2024;14:1369246.
  47. Lipton JH, Bryden P, Sidhu MK, et al. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res. 2015;39:58-64.
  48. Jabbour EJ, Sasaki K, Haddad FG, et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023;98:658-665.
  49. Hochhaus A, Rea D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617-626.